Sakabe. K K; Okuma. M M; Karaki. S S; Matsuura. S S; Yoshida. T T; Aikawa. H H; Izumi. S S; Kayama....
The study shows that both natural hormones like estrogen and manâmade chemicals that act like estrogen (such as BPA, certain plant compounds, and some livestock drugs) can lower the amount of thymosinâalphaâ1 that thymus cells make, likely by binding to estrogen receptors on those cells. This was seen in mouse cells in a lab dish, so it hints that high estrogenic exposure might blunt your bodyâs own production of this immuneâboosting peptide.
Naylor. P H PH; Smith. M R MR; Mutchnick. M G MG; Naylor. C W CW; Dosescu. J J; Skunca. M M; Moshier...
The study shows that the peptide thymosinâalphaâ1 (Tα1) does not make cancer cells grow faster or turn normal cells into cancer cells, whether itâs added from outside or made inside the cells themselves.
Franco. F J FJ; Diaz. C C; Barcia. M M; Freire. M M
The study shows that thymosinâalphaâ1 (Tα1) is a real, naturally occurring peptide found in the thymus and other tissues, not just a breakdown product of a larger protein. Itâs present in higher amounts than its precursor, prothymosinâalpha, and its levels stay the same even if you donât block enzymes during tissue processing.
Mastino. A A; Favalli. C C; Grelli. S S; Innocenti. F F; Garaci. E E
In mice, giving thymosinâalphaâ1 before interleukinâ2 makes immune cells better at killing cancerâlike cells, even in animals weakened by chemotherapy or tumors. The boost works for both easyâtoâkill and harderâtoâkill target cells, suggesting the two compounds together could act as a stronger immuneâstimulating combo.
Scientists discovered that the immuneâboosting peptide thymosinâalphaâ1 (Tα1) is actually made inside our bodies when a lysosomal enzyme called legumain cuts a larger protein, prothymosinâalpha. This shows Tα1 isnât just a lab artifactâit naturally exists in many tissues at levels similar to its precursor, hinting it has a real biological role.
Researchers made a slightly altered version of thymosinâalphaâ1 by swapping the last aminoâacid for its Dâform and adding an acetyl group at the start. This new peptide still helped weak Tâcells from kidneyâfailure patients respond better, and it stayed intact much longer in human serum than the regular peptide. The changes make the molecule more resistant to breakdown, which could mean a longerâlasting immune boost.
Zhang. Yuan-Yuan YY; Chen. En-Qiang EQ; Yang. Jin J; Duan. Yu-Rong YR; Tang. Hong H
A review of eight studies (583 patients) found that adding the peptide thymosinâalphaâ1 to the standard antiviral drug lamivudine improves liver enzyme normalization, virus suppression, and the chance that the hepatitis B virus marker (HBeAg) disappears, compared to lamivudine alone.
Navolotskaya. E V EV; Sadovnikov. V B VB; Zinchenko. D V DV; Zolotarev. Y A YA; Lipkin. V M VM; Zav'...
The study shows that thymosinâalphaâ1 (TMâα1) can bind to the same surface receptor on human Tâcells as cholera toxin Bâsubunit, and this binding boosts the activity of soluble guanylate cyclase (sGC), an enzyme linked to nitricâoxide signaling. The effect is seen at very low (nanomolar) concentrations, suggesting a potent interaction, but the work is done in isolated cells, not in living people.
Wang. S S SS; Wang. B S BS; Hughes. J L JL; Leopold. E J EJ; Wu. C R CR; Tam. J P JP
The paper describes a new recipe for cutting and cleaning peptides off a solid support using a mix of hydrogen bromide and trifluoroacetic acid, which works well for making large amounts of thymosinâalphaâ1, and shows that you can swap the usual toxic acetonitrile in HPLC purification for cheaper, safer isopropanol.
Zhou. Lin L; Pan. Li-Chao LC; Zheng. Yong-Gen YG; Du. Guo-Sheng GS; Fu. Xiao-Qian XQ; Zhu. Zhi-Dong...
A small retrospective study found that liver transplant patients with advanced liver cancer who received a combination of the drug sirolimus, the immuneâboosting peptide thymosinâalphaâ1 (called thymalfasin), and a mushroom extract (huaier granule) lived longer without the cancer coming back compared to those on standard tacrolimus therapy. The combo also lowered cancer marker AFP and reduced suppressive Târeg cells while boosting killer CD8+ T cells.
The study shows that two small proteins, thymosinâalphaâ1 and thymosinâbetaâ4, can make immune cells called macrophages better at showing antigens to Tâcells, which boosts Tâcell growth and ILâ2 production without raising ILâ4. This effect happens at very low, naturallyâoccurring concentrations, suggesting the peptides can enhance immune signaling, but the work was done in a lab dish, not in people.
Liu. Bo B; Gong. Xin X; Chang. Shaohong S; Sun. Peng P; Wu. Jun J
Scientists figured out a way to make the immuneâboosting peptide thymosinâalphaâ1 with its natural Nâterminal acetyl group using ordinary bacteria (E. coli) and a yeastâmade enzyme. The resulting peptide matches the chemicallyâsynthesized version in size and behavior, proving the method works.
Leichtling. K D KD; Serrate. S A SA; Sztein. M B MB
The study shows that the synthetic peptide thymosin alphaâ1 can boost the number of highâaffinity ILâ2 receptors on human immune cells, but only when those cells are already activated by a stimulant. It works best at very low (10â»ÂčÂČâŻM) and higher (10â»âžâŻM) concentrations, and it also raises ILâ2 production. However, the experiments were done in a testâtube with a lab chemical, not in people, so the realâworld dosing and benefits are still unclear.
Gravenstein. S S; Duthie. E H EH; Miller. B A BA; Roecker. E E; Drinka. P P; Prathipati. K K; Ershle...
Giving the immuneâboosting peptide thymosinâalphaâ1 alongside the flu shot helped older men (65â99 years) make more antibodies against the virus, and it didnât cause any noticeable side effects in the study.
Scientists made a new protein that joins two immuneâboosting peptides (thymosinâalphaâ1 and thymopentin) together. This combined peptide lasts longer in the blood (about 2âŻhours) than each piece on its own and showed stronger effects on mouse immune cells, suggesting it could be a more powerful immuneâsupport tool.
Hsia. J J; Sarin. N N; Oliver. J H JH; Goldstein. A L AL
The study shows that both aspirin and the peptide thymosinâalphaâ1 can boost the production of immuneâsignalling proteins ILâ2 and IFNâÎł by white blood cells, and that taking aspirin orally in healthy people also raises these cytokines in the blood. The effects are doseâdependent and seem to work through different mechanisms, suggesting they could be combined for stronger immune activation.
Scientists linked thymosinâalphaâ1 (a peptide that can boost immune function) to human serum albumin, creating two new fusion proteins that stay in the body much longer and still work to support immune cells in mice. The study shows these hybrids improve weight gain, spleen and thymus health, and antioxidant markers compared to the plain peptide.
The study shows that the peptide thymosinâalphaâ1 can push immune cells to grow by raising their oxidative stress, while it does the opposite in liver cancer cells, lowering their oxidative stress and stopping them from dividing. This dual action suggests it might help the immune system and also act as an antiâcancer agent, but the work was done in mouse immune cells and a human liver cancer cell line, not in people.
Torres-Alemán. I I; Rejas. M T MT; Barasoaín. I I; Borrell. J J; Guaza. C C
The study shows that thymosinâalphaâ1, a peptide from the thymus, can boost the release of the stress hormone corticosterone from rat adrenal cells, but only when another hormone (ACTH) is present. It doesnât raise hormone levels on its own, suggesting it works together with the bodyâs own stress signals.
Wang. S S SS; Chen. S T ST; Wang. K T KT; Merrifield. R B RB
The study shows a new way to make the peptide thymosinâalphaâ1 using Mozâprotected amino acids, which can be stripped off quickly with a mild acid mix, making the whole synthesis faster and cleaner than the older Boc method.